Risk Of Developing Liver Cancer After HCV Treatment

Tuesday, July 2, 2013

Health-related QOL poorer during early HCV treatment with addition of telaprevir



Health-related QOL poorer during early HCV treatment with addition of telaprevir
Healio
Vera-Llonch M. Aliment Pharmacol Ther. 2013;38:124-133.
 
July 1, 2013
Patients with chronic hepatitis C experienced a temporary decrease to health-related quality of life during interferon-based therapy that was more pronounced with the addition of telaprevir in a recent study.
 
Researchers evaluated the health-related quality of life (HRQOL) of 722 patients with chronic HCV genotype 1 enrolled in the multicenter, phase 3, placebo-controlled, double blind ADVANCE study. All patients were treatment-naive and received either 48 weeks of therapy with pegylated interferon alpha-2a and ribavirin (PR; n=359), or 12 weeks of telaprevir with either 24 (T12PR24; n=210) or 48 weeks (T12PR48; n=153) of PR.
Read more....
 
Preliminary results suggest safety, efficacy of tremelimumab as HCC, HCV therapy
Sangro B. J Hepatol. 2013;59:81-88.
July 2, 2013
 
Patients with hepatocellular carcinoma and chronic hepatitis C may experience antiviral and antitumoral benefits from treatment with tremelimumab, according to results of a recent pilot study.
In the phase 2, noncontrolled, multicenter, open-label trial, researchers administered 15 mg/kg tremelimumab intravenously daily to 21 adult patients with chronic HCV genotype 1b and hepatocellular carcinoma (HCC) for 90 days for a maximum of four cycles or until severe toxicity or tumor progression occurred. Toxicity was evaluable in 20 participants and tumor response was measurable in 17 cases.
Read more....

No comments:

Post a Comment